These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 29579623)

  • 1. Chemokines and cancer: new immune checkpoints for cancer therapy.
    Karin N
    Curr Opin Immunol; 2018 Apr; 51():140-145. PubMed ID: 29579623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCR8
    Barsheshet Y; Wildbaum G; Levy E; Vitenshtein A; Akinseye C; Griggs J; Lira SA; Karin N
    Proc Natl Acad Sci U S A; 2017 Jun; 114(23):6086-6091. PubMed ID: 28533380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.
    Chow MT; Ozga AJ; Servis RL; Frederick DT; Lo JA; Fisher DE; Freeman GJ; Boland GM; Luster AD
    Immunity; 2019 Jun; 50(6):1498-1512.e5. PubMed ID: 31097342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition.
    Varricchi G; Loffredo S; Marone G; Modestino L; Fallahi P; Ferrari SM; de Paulis A; Antonelli A; Galdiero MR
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skin-homing CLA+ T cells and regulatory CD25+ T cells represent major subsets of human peripheral blood memory T cells migrating in response to CCL1/I-309.
    Colantonio L; Iellem A; Sinigaglia F; D'Ambrosio D
    Eur J Immunol; 2002 Dec; 32(12):3506-14. PubMed ID: 12442333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.
    Gay F; D'Agostino M; Giaccone L; Genuardi M; Festuccia M; Boccadoro M; Bruno B
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):471-478. PubMed ID: 28689001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy.
    Sabio E; Chan TA
    Genome Med; 2019 Jul; 11(1):43. PubMed ID: 31340855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors: The linchpins of modern immunotherapy.
    Wilky BA
    Immunol Rev; 2019 Jul; 290(1):6-23. PubMed ID: 31355494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
    Maxwell R; Jackson CM; Lim M
    Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
    Mooradian MJ; Sullivan RJ
    Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Varied functions of immune checkpoints during cancer metastasis.
    Safarzadeh A; Alizadeh M; Beyranvand F; Falavand Jozaaee R; Hajiasgharzadeh K; Baghbanzadeh A; Derakhshani A; Argentiero A; Baradaran B; Silvestris N
    Cancer Immunol Immunother; 2021 Mar; 70(3):569-588. PubMed ID: 32902664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors in Organ Transplant Patients.
    Kittai AS; Oldham H; Cetnar J; Taylor M
    J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.
    Gide TN; Wilmott JS; Scolyer RA; Long GV
    Clin Cancer Res; 2018 Mar; 24(6):1260-1270. PubMed ID: 29127120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance for immunoregulation for long-term cancer control.
    Fusi A; Dalgleish A
    Future Oncol; 2017 Aug; 13(18):1619-1632. PubMed ID: 28776411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones?
    Karin N
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
    Wu X; Giobbie-Hurder A; Liao X; Connelly C; Connolly EM; Li J; Manos MP; Lawrence D; McDermott D; Severgnini M; Zhou J; Gjini E; Lako A; Lipschitz M; Pak CJ; Abdelrahman S; Rodig S; Hodi FS
    Cancer Immunol Res; 2017 Jan; 5(1):17-28. PubMed ID: 28003187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy.
    Vilgelm AE; Richmond A
    Front Immunol; 2019; 10():333. PubMed ID: 30873179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.
    Ren Z; Guo J; Liao J; Luan Y; Liu Z; Sun Z; Liu X; Liang Y; Peng H; Fu YX
    Clin Cancer Res; 2017 Jan; 23(1):193-203. PubMed ID: 27354469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4
    Liu S; Tao Z; Lou J; Li R; Fu X; Xu J; Wang T; Zhang L; Shang W; Mao Y; Wang F
    J Transl Med; 2023 Nov; 21(1):803. PubMed ID: 37950246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can rituximab unlock the innate potential of checkpoint blockade in the CNS?
    Rubenstein JL
    Leuk Lymphoma; 2019 Feb; 60(2):281-283. PubMed ID: 30188237
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.